Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Rises By 20.8%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 57,000 shares, an increase of 20.8% from the February 13th total of 47,200 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 225,700 shares, the days-to-cover ratio is currently 0.3 days.

Astellas Pharma Stock Up 0.7 %

Shares of Astellas Pharma stock opened at $9.96 on Tuesday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The company’s fifty day simple moving average is $9.66 and its two-hundred day simple moving average is $10.58. The company has a market cap of $18.02 billion, a P/E ratio of -45.26 and a beta of 0.29. Astellas Pharma has a 12-month low of $9.05 and a 12-month high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. Research analysts anticipate that Astellas Pharma will post 0.42 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.